Leukaemia treatment (FOI)

Request

Please answer the questions, excluding patients that receive treatment as part of clinical trials or private healthcare. 

Patients with acute myeloid leukaemia (AML) 

A

How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.

B

What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months? 

C

What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle).

D

What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months? 

Patients with chronic lymphocytic leukaemia (CLL)

E

Please complete the attached table based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.

Note: please provide data for the most recent 24-month period available via your prescribing/management system.

Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)

F

Please complete the attached table with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

G

Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

Response

A

Five patients have been prescribed Venetoclax for treatment of Acute Myeloid Leukaemia (AML) in the past 24 months.

B

The average daily dose of Venetoclax used in patients with AML is 100mg.

C

The average cycle length for patients receiving Venetoclax for AML is 28 days.

D

For the past 24 months, the average Venetoclax treatment duration for patients with AML is 7.2 months.

E and F

Please see the attached tables for the information requested:

Where patient numbers are small, disclosure control has been applied to protect the privacy of individuals and numbers fewer than five are represented as ‘<5’. Article 25 of the Freedom of Information (Jersey) Law 2011 has been applied.

Tables.pdf

G

Health and Community Services follow the NHS prescribing protocols for Venetoclax in the treatment of AML and Chronic Lymphocytic Leukaemia (CLL), as attached.

AzacitidineSC-Venetoclax.pdf

VenetoclaxHigh.pdf

VenetoclaxLow.pdf

VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

ObinutuzumabVenetoclax-LowRisk.pdf

Article applied

Article 25 - Personal information

(1) Information is absolutely exempt information if it constitutes personal data of which the applicant is the data subject as defined in the Data Protection (Jersey) Law 2018.

(2) Information is absolutely exempt information if –

(a) it constitutes personal data of which the applicant is not the data subject as defined in the Data Protection (Jersey) Law 2018; and

(b) its supply to a member of the public would contravene any of the data protection principles, as defined in that Law.